Az antidepresszívumok farmakogenetikája: A major depresszív zavar személyre szabott kezelése felé

Translated title of the contribution: Pharmacogenetics of antidepressive drugs: A way towards personalized treatment of major depressive disorder

Shira Weizman, X. Gonda, P. Döme, G. Faludi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of extensive ongoing research, we neither fully understand its etiopathological background, nor do we possess sufficient pharmacotherapeutic tools to provide remission for all patients. Depression is a heterogenous phenomenon both in its manifestation and its biochemical and genetic background with multiple systems involved. Similarly, the employed pharmaceutical agents in the treatment of depression also effect multiple neurotransmitter systems in the brain. However, we do not yet possess sufficient tools to be able to choose the medication that treats the symptoms most effectively while contributing to minimal side effects in parallel and thus provide personalized pharmacotherapy for depression. In the present paper we review genetic polymorphisms that may be involved in the therapeutic effects and side effects of antidepressive medications and which, in the future, may guide customized selection of the pharmacotherapeutic regimen in case of each patient.

Original languageHungarian
Pages (from-to)87-101
Number of pages15
JournalNeuropsychopharmacologia Hungarica
Volume14
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Pharmacogenetics
Major Depressive Disorder
Depression
Pharmaceutical Preparations
Therapeutic Uses
Genetic Polymorphisms
Neurotransmitter Agents
Psychiatry
Molecular Biology
Therapeutics
Drug Therapy
Brain
Research

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

@article{d7297e3e0ae048279d0742fe662a07a7,
title = "Az antidepressz{\'i}vumok farmakogenetik{\'a}ja: A major depressz{\'i}v zavar szem{\'e}lyre szabott kezel{\'e}se fel{\'e}",
abstract = "Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of extensive ongoing research, we neither fully understand its etiopathological background, nor do we possess sufficient pharmacotherapeutic tools to provide remission for all patients. Depression is a heterogenous phenomenon both in its manifestation and its biochemical and genetic background with multiple systems involved. Similarly, the employed pharmaceutical agents in the treatment of depression also effect multiple neurotransmitter systems in the brain. However, we do not yet possess sufficient tools to be able to choose the medication that treats the symptoms most effectively while contributing to minimal side effects in parallel and thus provide personalized pharmacotherapy for depression. In the present paper we review genetic polymorphisms that may be involved in the therapeutic effects and side effects of antidepressive medications and which, in the future, may guide customized selection of the pharmacotherapeutic regimen in case of each patient.",
keywords = "Antidepressants, Major depressive disorder, Pharmacogenetics, Polymorphisms",
author = "Shira Weizman and X. Gonda and P. D{\"o}me and G. Faludi",
year = "2012",
doi = "10.5706/nph201206002",
language = "Hungarian",
volume = "14",
pages = "87--101",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "2",

}

TY - JOUR

T1 - Az antidepresszívumok farmakogenetikája

T2 - A major depresszív zavar személyre szabott kezelése felé

AU - Weizman, Shira

AU - Gonda, X.

AU - Döme, P.

AU - Faludi, G.

PY - 2012

Y1 - 2012

N2 - Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of extensive ongoing research, we neither fully understand its etiopathological background, nor do we possess sufficient pharmacotherapeutic tools to provide remission for all patients. Depression is a heterogenous phenomenon both in its manifestation and its biochemical and genetic background with multiple systems involved. Similarly, the employed pharmaceutical agents in the treatment of depression also effect multiple neurotransmitter systems in the brain. However, we do not yet possess sufficient tools to be able to choose the medication that treats the symptoms most effectively while contributing to minimal side effects in parallel and thus provide personalized pharmacotherapy for depression. In the present paper we review genetic polymorphisms that may be involved in the therapeutic effects and side effects of antidepressive medications and which, in the future, may guide customized selection of the pharmacotherapeutic regimen in case of each patient.

AB - Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of extensive ongoing research, we neither fully understand its etiopathological background, nor do we possess sufficient pharmacotherapeutic tools to provide remission for all patients. Depression is a heterogenous phenomenon both in its manifestation and its biochemical and genetic background with multiple systems involved. Similarly, the employed pharmaceutical agents in the treatment of depression also effect multiple neurotransmitter systems in the brain. However, we do not yet possess sufficient tools to be able to choose the medication that treats the symptoms most effectively while contributing to minimal side effects in parallel and thus provide personalized pharmacotherapy for depression. In the present paper we review genetic polymorphisms that may be involved in the therapeutic effects and side effects of antidepressive medications and which, in the future, may guide customized selection of the pharmacotherapeutic regimen in case of each patient.

KW - Antidepressants

KW - Major depressive disorder

KW - Pharmacogenetics

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84862838333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862838333&partnerID=8YFLogxK

U2 - 10.5706/nph201206002

DO - 10.5706/nph201206002

M3 - Article

C2 - 22710850

AN - SCOPUS:84862838333

VL - 14

SP - 87

EP - 101

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 2

ER -